Creative Medical Technology Holdings (NASDAQ: CELZ) has recently released its full year 2023 results, showing that revenue exceeded analyst expectations by an impressive 50%. However, earnings per share (EPS) fell short by 2.2%. Despite this, the company’s future looks promising, with revenue forecasted to grow by an average of 61% per year over the next three years. This growth rate is significantly higher than the 17% growth forecast for the Biotechs industry in the US.
Investors should be aware of the risks associated with investing in Creative Medical Technology Holdings. While there are many positive signs about this company, there are also several warning signs that investors should take seriously. Two of these warning signs are particularly significant and should be carefully considered before making any investment decisions.
One of these warning signs is that Creative Medical Technology Holdings’ shares have been down by 3.2% from a week ago. This may indicate a loss of investor confidence or other negative factors affecting the company’s performance. It is important for investors to carefully consider these risks before deciding whether or not to invest in this company.
Another warning sign is that Creative Medical Technology Holdings has been identified as having three significant risks associated with it. These risks should be taken seriously and carefully considered before making any investment decisions. Understanding these risks is an important part of the investment process and can help investors make informed decisions about their investments.
